GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medy-Tox Inc (XKRX:086900) » Definitions » Cyclically Adjusted PS Ratio

Medy-Tox (XKRX:086900) Cyclically Adjusted PS Ratio : 4.74 (As of May. 15, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Medy-Tox Cyclically Adjusted PS Ratio?

As of today (2024-05-15), Medy-Tox's current share price is ₩135500.00. Medy-Tox's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₩28,591.20. Medy-Tox's Cyclically Adjusted PS Ratio for today is 4.74.

The historical rank and industry rank for Medy-Tox's Cyclically Adjusted PS Ratio or its related term are showing as below:

XKRX:086900' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.02   Med: 8.78   Max: 56.53
Current: 4.74

During the past years, Medy-Tox's highest Cyclically Adjusted PS Ratio was 56.53. The lowest was 4.02. And the median was 8.78.

XKRX:086900's Cyclically Adjusted PS Ratio is ranked better than
54.58% of 513 companies
in the Biotechnology industry
Industry Median: 5.58 vs XKRX:086900: 4.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medy-Tox's adjusted revenue per share data for the three months ended in Dec. 2023 was ₩8,601.523. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₩28,591.20 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medy-Tox Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Medy-Tox's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medy-Tox Cyclically Adjusted PS Ratio Chart

Medy-Tox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.12 8.67 6.33 5.07 8.43

Medy-Tox Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.07 8.49 8.79 9.03 8.43

Competitive Comparison of Medy-Tox's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Medy-Tox's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medy-Tox's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medy-Tox's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medy-Tox's Cyclically Adjusted PS Ratio falls into.



Medy-Tox Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medy-Tox's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=135500.00/28591.2
=4.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medy-Tox's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Medy-Tox's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=8601.523/118.8477*118.8477
=8,601.523

Current CPI (Dec. 2023) = 118.8477.

Medy-Tox Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2,001.090 99.253 2,396.149
201406 2,423.557 99.353 2,899.099
201409 4,885.646 99.608 5,829.329
201412 2,186.452 99.098 2,622.200
201503 2,867.592 99.720 3,417.637
201506 3,336.730 100.050 3,963.645
201509 3,513.669 100.110 4,171.326
201512 3,785.818 100.220 4,489.481
201603 4,394.480 100.560 5,193.654
201606 4,819.519 100.790 5,682.992
201609 5,048.983 101.460 5,914.252
201612 6,132.826 101.560 7,176.765
201703 6,225.339 102.850 7,193.653
201706 7,314.397 102.610 8,471.877
201709 6,211.829 103.490 7,133.651
201712 8,162.840 102.990 9,419.699
201803 9,072.907 104.100 10,358.253
201806 8,478.348 104.130 9,676.675
201809 7,437.694 105.650 8,366.804
201812 7,575.174 104.350 8,627.619
201903 6,823.869 104.490 7,761.519
201906 8,497.891 104.880 9,629.622
201909 7,485.442 105.200 8,456.536
201912 10,223.185 105.120 11,558.238
202003 5,273.009 105.540 5,937.891
202006 6,476.203 104.870 7,339.390
202009 7,066.709 106.200 7,908.306
202012 5,701.014 105.765 6,406.182
202103 4,977.074 107.357 5,509.773
202106 6,730.765 107.579 7,435.828
202109 11,072.207 108.759 12,099.265
202112 7,187.882 109.676 7,788.943
202203 6,565.846 111.806 6,979.385
202206 7,812.385 114.083 8,138.685
202209 8,487.785 114.831 8,784.658
202212 8,384.473 115.200 8,649.944
202303 7,070.621 116.550 7,210.038
202306 7,703.145 117.140 7,815.450
202309 8,915.390 119.111 8,895.667
202312 8,601.523 118.848 8,601.523

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medy-Tox  (XKRX:086900) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medy-Tox Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Medy-Tox's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medy-Tox (XKRX:086900) Business Description

Industry
Traded in Other Exchanges
N/A
Address
641-4, Gak-Ri, Ochang-Eup, Cheongwon, KOR, 363885
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Medy-Tox (XKRX:086900) Headlines

No Headlines